Soliris sales drive Alexion's Q3 earnings beyond the loftiest expectations
- Alexion's revenues for Q3 2014 increased 39% compared with Q3 2013 for total quarterly earnings of $555.1 million.
- All of Alexion's earnings for the quarter were from Soliris (eculizumab), which is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
- Q3 2014 GAAP increased 87% to $0.88/share, compared with $0.47/share in Q3 2013.
Even the most optimistic predictions fell short of Alexion's actual third quarter performance. All $555.1 million in third quarter revenues were attributable to Soliris sales, which have increased as more patients—in 50 different countries—are treated for PNH and aHUS.
Alexion's R&D expenses were 35.4% higher quarter-over-quarter, as the company continued to look towards the future. Within the next five years, Alexion is anticipating seven product approvals, including the biologic asfotase alfa, as well as several other products and new indications for Soliris.